2-[(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)methyl-methylamino]acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-[(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)methyl-methylamino]acetic acid
• 化学式: C₂₁H₂₅NO₃
• 分子量: 339.4
• InChiKey: UEBBYLJZCHTLEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE
  申请人：Arizona Board of Regents, for and on behalf of, Arizona State University

  公开号：US20150141462A1

  公开（公告）日：2015-05-21

  The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier. The present invention also relates to methods for treating drug addiction and preventing a drug relapse in a patient. The methods comprise (a) administering to the patient a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; (b) administering to the patient a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
• METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20210254158A1

  公开（公告）日：2021-08-19

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.
• US6410592B1
  申请人：——

  公开号：US6410592B1

  公开（公告）日：2002-06-25
• [EN] A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY<br/>[FR] PROCÉDÉ POUR PRÉDIRE LA RÉPONSE D'UN PATIENT À UN TRAITEMENT PAR MODULATEURS DE SLC
  申请人：UNIV COLUMBIA

  公开号：WO2019046303A1

  公开（公告）日：2019-03-07

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.
• [EN] COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA POLYCYTHÉMIE
  申请人：[en]DISC MEDICINE, INC.

  公开号：WO2022192730A1

  公开（公告）日：2022-09-15

  The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating polycythemia, and related syndromes thereof.